Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a Study of STSA-1002 in Healthy Subjects
NCT05032144Phase 1Completed
- Sponsor
- Staidson Biopharmaceutical
- Start
- Sep 2021
- Primary completion
- Mar 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of STSA-1002 in acute respiratory distress syndrome (ARDS) (5 cohorts), sponsored by Staidson Biopharmaceutical. Primary endpoints: Incidence of Adverse Events, Clinically Significant Laboratory Abnormalities, Clinically Significant Electrocardiogram Abnormalities, Clinically Significant Vital Signs Abnormalities And Clinically…, Maximum plasma concentration and 6 more. Started Sep 2021; status: completed.
02
Drugs
STSA-1002
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05032144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05032144.